Stockscreener 앱 받기
23.35
0.55%
-0.13
시간 외 거래:
23.35
전일 마감가:
$23.48
열려 있는:
$23.5
하루 거래량:
852.38K
Relative Volume:
1.24
시가총액:
$918.77M
수익:
$734.86M
순이익/손실:
$5.14M
주가수익비율:
186.80
EPS:
0.125
순현금흐름:
$132.71M
1주 성능:
+3.14%
1개월 성능:
-6.15%
6개월 성능:
+1.30%
1년 성능:
-10.43%
1일 변동 폭
$23.24
$23.74
1주일 범위
$21.92
$23.86
52주 변동 폭
$18.80
$27.64
Pacira Biosciences Inc Stock (PCRX) Company Profile
명칭
Pacira Biosciences Inc
전화
650-242-8052
주소
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
23.35 | 923.89M | 734.86M | 5.14M | 132.71M | 0.125 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Equal Weight |
| 2025-11-17 | 개시 | H.C. Wainwright | Buy |
| 2025-07-25 | 업그레이드 | Truist | Hold → Buy |
| 2025-01-30 | 업그레이드 | Truist | Sell → Hold |
| 2024-08-13 | 다운그레이드 | Truist | Buy → Sell |
| 2024-08-12 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2024-08-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-07 | 재개 | JP Morgan | Overweight |
| 2023-12-20 | 개시 | Raymond James | Outperform |
| 2023-08-03 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | 재개 | Wedbush | Outperform |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-01-03 | 재개 | JP Morgan | Overweight |
| 2021-07-26 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-04-21 | 재개 | JP Morgan | Neutral |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | 재확인 | Needham | Buy |
| 2020-05-27 | 개시 | Guggenheim | Neutral |
| 2020-04-07 | 개시 | Northland Capital | Outperform |
| 2020-03-20 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-24 | 개시 | SunTrust | Buy |
| 2020-01-23 | 개시 | SunTrust | Buy |
| 2019-11-06 | 개시 | BTIG Research | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-06 | 업그레이드 | Mizuho | Underperform → Neutral |
| 2019-05-02 | 업그레이드 | Stifel | Sell → Hold |
| 2019-02-01 | 다운그레이드 | Mizuho | Neutral → Underperform |
| 2018-08-06 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-21 | 재확인 | Mizuho | Neutral |
| 2018-02-16 | 다운그레이드 | Needham | Buy → Hold |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2018-01-04 | 재확인 | Canaccord Genuity | Buy |
| 2018-01-03 | 개시 | Leerink Partners | Mkt Perform |
모두보기
Pacira Biosciences Inc 주식(PCRX)의 최신 뉴스
Pacira shareholders lobbied by hedge fund board nominees - MSN
PCRX Stock Chart | PACIRA BIOSCIENCES INC (NASDAQ:PCRX) - ChartMill
[DFAN14A] Pacira BioSciences, Inc. SEC Filing - Stock Titan
DOMA Perpetual Capital Issues a Press Release to Pacira BioSciences Shareholders - marketscreener.com
Doma Perpetual urges Pacira BioSciences shareholders to judge sale price adequacy - marketscreener.com
Doma Perpetual Urges Pacira Biosciences Shareholders To Judge Sale Price Adequacy - TradingView
A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC - PR Newswire
DOMA Perpetual Issues a Press Release to Shareholders of Pacira BioSciences - marketscreener.com
PCRX: DOMA Capital Advocates for Change in Pacira BioSciences Bo - GuruFocus
DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences - Nasdaq
Pacira Biosciences Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Pacira BioSciences Issues Investor Presentation for Shareholders - marketscreener.com
Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders - The Manila Times
Pacira BioSciences Files Investor Presentation Highlighting - GlobeNewswire
Pacira Q1 earnings miss estimates on higher costs, revenues rise y/y - MSN
Do options traders know something about Pacira BioSciences stock we don't? - MSN
Pacira BioSciences: Exparel Still Supports My Original Bull Case (NASDAQ:PCRX) - Seeking Alpha
Pacira BioSciences, Inc.Common Stock (NQ: PCRX - The Chronicle-Journal
(PCRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Pacira BioSciences stock (US6951271005): Activist investor DOMA nominates three board directors - AD HOC NEWS
UBS Group AG Has $14.46 Million Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciencesAlong with its Definitive Proxy Statement & WHITE Proxy CardUrging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board Candidates - Sahm
DOMA Perpetual nominates three directors to Pacira board By Investing.com - Investing.com India
Concerns Rise Over Pacira BioSciences' (PCRX) Board Management S - GuruFocus
Pacira BioSciences' (NASDAQ:PCRX) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
DOMA Perpetual nominates three directors to Pacira board - Investing.com UK
Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences - Yahoo Finance
Vanguard Group Inc. Sells 384,612 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat
DOMA Perpetual Capital Solicits Proxies from Shareholders of Pacira BioSciences - marketscreener.com
Pacira BioSciences sends letter to stockholders reiterating superior qualifications of its board nominees - marketscreener.com
Pacira Biosciences Sends Letter To Stockholders Reiterating Superior Qualifications Of Its Board Nominees - TradingView
Activist DOMA (PCRX) Seeks CEO Removal, Board Seats; Pushes Sale Vote - Stock Titan
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees - GlobeNewswire
HC Wainwright Expects Lower Earnings for Pacira BioSciences - MarketBeat
Pacira Q1 2026 slides: EXPAREL growth accelerates, margins compress By Investing.com - Investing.com Australia
Earnings call transcript: Pacira BioSciences Q1 2026 earnings exceed forecasts - Investing.com UK
Earnings call transcript: Pacira BioSciences Q1 2026 earnings exceed forecasts By Investing.com - Investing.com Australia
Pacira BioSciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
10 new Pacira hires get stock options and restricted units - Stock Titan
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Pacira BioSciences Reports Strong Q1 2026 Results and Highlights Success of 5x30 Strategy, Urges Stockholders to Vote "FOR" Board Nominees - Quiver Quantitative
Pacira BioSciences Mails Letter to Stockholders - The Manila Times
PACIRA BIOSCIENCES INC (NASDAQ:PCRX): A Value Stock Candidate with Margin of Safety - ChartMill
Contact - FinancialContent
MSN Money - MSN
How Pacira’s Q1 2026 Results, EXPAREL Data and Proxy Battle May Impact Pacira BioSciences (PCRX) Investors - Sahm
Price-Driven Insight from (PCRX) for Rule-Based Strategy - Stock Traders Daily
Assessing Pacira BioSciences (PCRX) Valuation After Earnings Update And New EXPAREL Real World Data - Yahoo Finance
Pacira Biosciences Q1 Non-GAAP Earnings Fall, Revenue Rises; 2026 Sales Forecast Maintained - Moomoo
Universal Beteiligungs und Servicegesellschaft mbH Boosts Stock Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira Biosciences Inc (PCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.92%
4.44%
자본화:
|
볼륨(24시간):